A mini-review of risk factors for developmental dysplasia of the hip: insights from multiple comparative cohort studies.

J Pediatr Orthop BJun 12, 2026 (epub)
Clinical ResearchOrthopedic SurgeryPediatrics

Thomas Cho, Ajay Nair, Phillip Stokey et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated risk factors for developmental dysplasia of the hip (DDH) using data from 22 comparative cohort studies involving 133,108 participants. It found that breech presentation, family history of DDH, oligohydramnios, and female sex significantly increased the risk of DDH, with relative risks ranging from 3.35 to 3.74. The study highlights the need for targeted screening in at-risk infants.

Key findings

  • Breech presentation was associated with a relative risk of 3.35 for DDH.
  • Family history of DDH increased the risk with a relative risk of 3.64.
  • Oligohydramnios showed a relative risk of 3.59 for developing DDH.
  • Female sex was linked to a relative risk of 3.74 for DDH.

Why it matters

Understanding the quantitative strength of these risk factors allows clinicians to identify infants at higher risk for developmental dysplasia of the hip, facilitating early intervention and management.

Source

PubMed · PMID 42290084

Published in J Pediatr Orthop B. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.